Canada

QurCan will focus on developing and optimising genetic therapeutics using its delivery technology, while Lilly will take responsibility for advancing selected candidates through subsequent development stages.

The 72,300 square foot facility is the largest single site contract development and manufacturing organisation (CDMO) facility in North America dedicated to radiopharmaceutical development, according to AtomVie.

The company’s focus on both non-potent and high-potency APIs reflects the range of projects handled at the site, from conventional small-molecule development to programs requiring additional containment and specialized handling.

The collaboration will focus on designing next-generation photosensitisers for photodynamic therapy (PDT), a treatment that uses light-activated drugs to target and destroy tumour cells.

The project is backed by a conditional grant of up to C$5 million (US$3.6 million) from the Ontario government through the Invest Ontario Fund.

Under the renewed agreement, Bora will provide end-to-end manufacturing services for more than 20 commercial GSK product lines.

Eydenzelt will be available in both pre-filled syringe and vial formats, and it is approved for all the same uses as the original Eylea treatment.